Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production

Novo Nordisk has been staffing up its sales and marketing teams in the U.S. at a time when bigger rivals are cutting back. Turns out, the Danish drugmaker has big plans for expansion back home as well.

Pfizer lost its AstraZeneca bid purely on price, CFO says. What else?

Want to know why the potential Pfizer-AstraZeneca marriage failed? Price, says Pfizer CFO Frank D'Amelio. Stating the obvious, obviously. But in balking at Pfizer's offer, AstraZeneca--and allies in the U.K.--raised plenty of other issues. Emotional issues, for some.

AstraZeneca investors press exec-comp chair to tie pay to Pfizer bid

Several top AstraZeneca shareholders are pressing for meetings with John Varley, the former CEO of Barclays bank who also happens to head up the drugmaker's remuneration committee, Sky News reports. The aim? To follow through on calls to link AstraZeneca executive pay to the value of Pfizer's rejected buyout offer.

Dartmouth profs take issue with calls for testosterone testing

Drugmakers are touting testosterone testing as part of Men's Health Week, drawing fire from a pair of Dartmouth professors via a Cochrane Group blog.

Japanese authorities arrest ex-Novartis employee in data-manipulation scandal

Japanese police brought in Nobuo Shiraishi, a former Novartis worker linked to discredited studies of the company's blood pressure drug Diovan. Shiraishi is suspected of violating the country's pharma laws by providing false data to researchers, Tokyo prosecutors said in a statement.

Orexigen obesity med faces uphill fight--and that's if it's approved

If Orexigen wins FDA approval for its new weight loss drug, how will it and its pharma partner Takeda take on the obesity market?

MS docs, activists pressure U.K. cost watchdog to bless Biogen, GW meds

The U.K.'s cost-effectiveness agency is accustomed to boos and hisses. The National Institute for Health and Care Excellence often turns down new treatments it considers too expensive for their payoff in patients. So, will a campaign by patient advocates sway its opinion on two new multiple sclerosis drugs?

Boehringer's lung drug gets a boost from European regulators

Boehringer Ingelheim persuaded EU officials to put its lung-disease drug nintedanib on its development fast track, speeding its path to market as a treatment for idiopathic pulmonary fibrosis.

Italian fraud squad raids drug agency in Roche-Novartis probe

Italian finance police searched the offices of the Italian Medicines Agency, looking for evidence in a criminal probe of potential fraud and market manipulation by the Swiss drugmakers Novartis and Roche. Officials have been investigating allegations that the two companies colluded to boost sales of Lucentis, their eye drug, by sidelining off-label use of the drug's close cousin, Avastin.

Bayer drafts Otsuka exec to lead pharma biz to big growth

Bayer's pharma division has a new president with a big task ahead of him. A week after the company announced its current leader, Andreas Fibig, would jump ship, Bayer says it's chosen an Otsuka Pharmaceutical executive to take the post.